Inhibrx Approve Sale Of INBRX-101 To Sanofi; Sanofi To Acquire All Outstanding Shares Of Inhibrx Through Merger And Each Inhibrx Stockholder To Receive $30/Share
Portfolio Pulse from Benzinga Newsdesk
Inhibrx has approved the sale of its drug INBRX-101 to Sanofi. Additionally, Sanofi will acquire all outstanding shares of Inhibrx through a merger, with each Inhibrx stockholder receiving $30 per share.
May 24, 2024 | 8:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inhibrx has approved the sale of its drug INBRX-101 to Sanofi and will be acquired by Sanofi at $30 per share.
The acquisition by Sanofi at a premium price of $30 per share is likely to positively impact Inhibrx's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100